Markets

MyoKardia (MYOK) in Focus: Stock Moves 7.3% Higher

MyoKardia, Inc.MYOK was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company -as the stock is now up 22.5% in the past one-month time frame.

The move came after the company announced positive efficacy, safety and biomarker data for its investigational drug, mavacamten.

The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

MyoKardia currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

MyoKardia, Inc. Price

MyoKardia, Inc. Price | MyoKardia, Inc. Quote

Investors interested in the Medical - Biomedical and Genetics industry may consider a better-ranked stock like Celcuity, Inc. CELC , which carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .

Is MYOK going up? Or down? Predict to see what others think: Up or Down

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They're also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

MyoKardia, Inc. (MYOK): Free Stock Analysis Report

Celcuity, Inc. (CELC): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

MYOK CELC

Other Topics

Investing Stocks

Latest Markets Videos